Efficacy and safety of bevacizumab biosimilars versus original drugs for patients with metastatic colorectal cancer:a Meta-analysis
10.19960/j.issn.1005-0698.202312010
- VernacularTitle:贝伐珠单抗生物类似药与原研药在转移性结直肠癌患者中疗效和安全性的Meta分析
- Author:
En-Hui WEN
1
;
Ying LI
;
Zhi-Ying WANG
;
Li-Hui LONG
Author Information
1. 西安医学院第一附属医院临床药学室(西安 710077)
- Keywords:
Bevacizumab;
Biosimilar;
Metastatic colorectal cancer;
Meta-analysis;
Randomized controlled trial
- From:
Chinese Journal of Pharmacoepidemiology
2023;32(12):1401-1407
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically review the efficacy and safety of bevacizumab biosimilars versus original drugs in treatment of metastatic colorectal cancer.Methods PubMed,Embase,Cochrane Library,CNKI,WanFang Data,VIP and SinoMed databases were electronically searched to collect the randomized controlled trials(RCTs)of bevacizumab biosimilar in patients with metastatic colorectal cancer from inception to June 18,2023.Two reviewers independently screened the literature,extracted data,and assessed the risk of bias of the included studies,and a meta-analysis was conducted using Stata 17.0 software.Results A total of 4 RCTs involving 1 052 patients were included.The results of meta-analysis showed that no significant difference was found in overall response rate(RD=﹣0.01,95%CI ﹣0.06 to 0.05,P=0.86),progression free survival(HR=1.00,95%CI 0.91 to 1.09,P=0.94),the total incidence of adverse drug reactions(RR=1.05,95%CI 0.85 to 1.31,P=0.91)and the incidence of severe adverse events(RR=0.886,95%CI 0.377 to 2.081,P=0.60)between bevacizumab biosimilars group and original drugs group.Conclusion The current evidence shows that bevacizumab biosimilar is equivalent to original drugs in treatment of metastatic colorectal cancer.Due to limited quality and quantity of the included studies,more high quality studies are required to verify the above conclusions.
